Page last updated: 2024-10-21

urea and Allodynia

urea has been researched along with Allodynia in 25 studies

pseudourea: clinical use; structure
isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.

Research Excerpts

ExcerptRelevanceReference
" The 5-isoquinoline-containing compound 14a (hTRPV1 IC50 = 4 nM) exhibited 46% oral bioavailability and in vivo activity in animal models of visceral and inflammatory pain."5.33Novel transient receptor potential vanilloid 1 receptor antagonists for the treatment of pain: structure-activity relationships for ureas with quinoline, isoquinoline, quinazoline, phthalazine, quinoxaline, and cinnoline moieties. ( Bayburt, EK; Didomenico, S; Drizin, I; Faltynek, CR; Gomtsyan, A; Hannick, SM; Honore, P; Jarvis, MF; Jinkerson, T; Koenig, JR; Lee, CH; Macri, BS; Marsh, KC; McDonald, HA; Oie, T; Perner, RJ; Schmidt, RG; Stewart, KD; Surowy, CS; Turner, S; Wetter, J; Wismer, CT; Zheng, GZ, 2005)
" Furthermore, A-425619 maintained efficacy in the postoperative pain model after twice daily dosing p."5.33A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel transient receptor potential type V1 receptor antagonist, relieves pathophysiological pain associated with inflammation and tissue injury in rats. ( El Kouhen, R; Faltynek, CR; Gauvin, DM; Gomtsyan, A; Honore, P; Jarvis, MF; Lee, CH; Marsh, K; Mikusa, J; Sullivan, JP; Wismer, CT; Zhong, C; Zhu, CZ, 2005)
" Previously, we demonstrated that DAGLβ inactivation using the triazole urea inhibitor KT109 blocked macrophage inflammatory signaling and reversed allodynic responses of mice in inflammatory and neuropathic pain models."3.88Liposomal Delivery of Diacylglycerol Lipase-Beta Inhibitors to Macrophages Dramatically Enhances Selectivity and Efficacy in Vivo. ( Donvito, G; Fox, TE; Hsu, KL; Kester, M; Lichtman, AH; Schurman, LD; Shin, M; Snyder, HW, 2018)
"Oxaliplatin-induced cold allodynia was alleviated by the TRPM8 blockers N-(2-aminoethyl)-N-[4-(benzyloxy)-3-methoxybenzyl]-N'-(1S)-1-(phenyl) ethyl] urea and TC-I 2014."3.83Involvement of c-Myc-mediated transient receptor potential melastatin 8 expression in oxaliplatin-induced cold allodynia in mice. ( Andoh, T; Kuraishi, Y; Mizoguchi, S; Yakura, T, 2016)
" In all models, URB937 was as effective or more effective than standard analgesic and anti-inflammatory drugs (indomethacin, gabapentin, dexamethasone) and reversed pain-related responses (mechanical hyperalgesia, thermal hyperalgesia, and mechanical allodynia) in a dose-dependent manner."3.78Peripheral FAAH inhibition causes profound antinociception and protects against indomethacin-induced gastric lesions. ( Armirotti, A; Bandiera, T; Bertorelli, R; Colombano, G; Moreno-Sanz, G; Piomelli, D; Reggiani, A; Sasso, O; Scarpelli, R, 2012)
"Vanilloid receptor type 1 (TRPV1) is a ligand-gated nonselective cation channel that is considered to be an important integrator of various pain stimuli such as endogenous lipids, capsaicin, heat, and low pH."3.73TRPV1 receptors in the CNS play a key role in broad-spectrum analgesia of TRPV1 antagonists. ( Bayburt, EK; Bianchi, B; Brown, B; Chandran, P; Cui, M; Decker, MW; Faltynek, CR; Gauvin, D; Gomtsyan, A; Hernandez, G; Honore, P; Lee, CH; Marsh, K; McDonald, H; Mikusa, J; Moreland, RB; Neelands, TR; Niforatos, W; Sullivan, JP; Zhong, C, 2006)
" SB-705498 is a potent, selective and orally bioavailable TRPV1 antagonist with demonstrated efficacy in a number of preclinical pain models."2.73The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans. ( Appleby, JM; Aylott, MC; Brooke, AC; Bullman, JN; Chizh, BA; Gray, EJ; Lai, RY; Napolitano, A; O'Donnell, MB; Wang, J; Williams, PM, 2007)
"Mechanical allodynia and thermal hyperalgesia were evaluated using von Frey filaments and a thermal stimulus."1.56Chemical stimulation of the lateral hypothalamus induces antiallodynic and anti-thermal hyperalgesic effects in animal model of neuropathic pain: Involvement of orexin receptors in the spinal cord. ( Haghparast, A; Kashfi, K; Manaheji, H; Salehi, S, 2020)
"Meanwhile, thermal hyperalgesia was observed from day 2 through day 10 and mechanical allodynia from day 4 through day 10."1.40Glycogen synthase kinase 3 beta regulates glial glutamate transporter protein expression in the spinal dorsal horn in rats with neuropathic pain. ( Gao, M; Maixner, DW; Weng, HR, 2014)
"Pain is the leading cause of emergency department visits, hospitalizations, and daily suffering in individuals with sickle cell disease (SCD)."1.37Transient receptor potential vanilloid 1 mediates pain in mice with severe sickle cell disease. ( Barabas, ME; Brandow, AM; Hillery, CA; Kerstein, PC; Retherford, D; Stucky, CL; Vilceanu, D; Wandersee, NJ, 2011)
"Assessment of RTX hyperalgesia by measurement of the paw withdrawal latency with a plantar test apparatus yielded 30 mg/kg minimum effective dose for each antagonist."1.36Effect of transient receptor potential vanilloid 1 (TRPV1) receptor antagonist compounds SB705498, BCTC and AMG9810 in rat models of thermal hyperalgesia measured with an increasing-temperature water bath. ( Bölcskei, K; Dézsi, L; Horváth, C; Kis-Varga, A; Petho, G; Szentirmay, E; Szolcsányi, J; Tékus, V; Visegrády, A, 2010)
" The 5-isoquinoline-containing compound 14a (hTRPV1 IC50 = 4 nM) exhibited 46% oral bioavailability and in vivo activity in animal models of visceral and inflammatory pain."1.33Novel transient receptor potential vanilloid 1 receptor antagonists for the treatment of pain: structure-activity relationships for ureas with quinoline, isoquinoline, quinazoline, phthalazine, quinoxaline, and cinnoline moieties. ( Bayburt, EK; Didomenico, S; Drizin, I; Faltynek, CR; Gomtsyan, A; Hannick, SM; Honore, P; Jarvis, MF; Jinkerson, T; Koenig, JR; Lee, CH; Macri, BS; Marsh, KC; McDonald, HA; Oie, T; Perner, RJ; Schmidt, RG; Stewart, KD; Surowy, CS; Turner, S; Wetter, J; Wismer, CT; Zheng, GZ, 2005)
" Furthermore, A-425619 maintained efficacy in the postoperative pain model after twice daily dosing p."1.33A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel transient receptor potential type V1 receptor antagonist, relieves pathophysiological pain associated with inflammation and tissue injury in rats. ( El Kouhen, R; Faltynek, CR; Gauvin, DM; Gomtsyan, A; Honore, P; Jarvis, MF; Lee, CH; Marsh, K; Mikusa, J; Sullivan, JP; Wismer, CT; Zhong, C; Zhu, CZ, 2005)
"Because NMDA activity mediates hyperalgesia, we tested the hypothesis that PAR-1 receptors also regulate pain processing."1.32Thrombin inhibits NMDA-mediated nociceptive activity in the mouse: possible mediation by endothelin. ( Fang, M; Fisher, LL; Kovács, KJ; Larson, AA, 2003)

Research

Studies (25)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's11 (44.00)29.6817
2010's10 (40.00)24.3611
2020's4 (16.00)2.80

Authors

AuthorsStudies
Xu, WJ1
Wang, YY1
Zhao, Y1
Jia, H1
Tang, JS1
Huo, FQ1
Liu, H1
Salehi, S1
Kashfi, K1
Manaheji, H1
Haghparast, A1
Matsuura, W1
Nakamoto, K1
Tokuyama, S1
Cagli, A1
Senol, SP1
Temiz-Resitoglu, M1
Guden, DS1
Sari, AN1
Sahan-Firat, S1
Tunctan, B1
Shin, M1
Snyder, HW1
Donvito, G1
Schurman, LD1
Fox, TE1
Lichtman, AH1
Kester, M1
Hsu, KL1
Araldi, D1
Ferrari, LF1
Levine, JD1
Weng, HR1
Gao, M1
Maixner, DW1
Wardach, J1
Wagner, M1
Jeong, Y1
Holden, JE1
Mizoguchi, S1
Andoh, T1
Yakura, T1
Kuraishi, Y1
Tékus, V1
Bölcskei, K1
Kis-Varga, A1
Dézsi, L1
Szentirmay, E1
Visegrády, A1
Horváth, C1
Szolcsányi, J1
Petho, G1
Adedoyin, MO1
Vicini, S1
Neale, JH1
Hillery, CA1
Kerstein, PC1
Vilceanu, D1
Barabas, ME1
Retherford, D1
Brandow, AM1
Wandersee, NJ1
Stucky, CL1
Sasso, O1
Bertorelli, R1
Bandiera, T1
Scarpelli, R1
Colombano, G1
Armirotti, A1
Moreno-Sanz, G1
Reggiani, A1
Piomelli, D1
Mazzardo-Martins, L1
Martins, DF1
Stramosk, J1
Cidral-Filho, FJ1
Santos, AR1
Fang, M1
Kovács, KJ1
Fisher, LL1
Larson, AA1
Gomtsyan, A3
Bayburt, EK2
Schmidt, RG1
Zheng, GZ1
Perner, RJ1
Didomenico, S1
Koenig, JR1
Turner, S1
Jinkerson, T1
Drizin, I1
Hannick, SM1
Macri, BS1
McDonald, HA1
Honore, P3
Wismer, CT2
Marsh, KC1
Wetter, J1
Stewart, KD1
Oie, T1
Jarvis, MF3
Surowy, CS1
Faltynek, CR4
Lee, CH3
Mikusa, J2
Zhu, CZ1
Zhong, C2
Gauvin, DM1
El Kouhen, R1
Marsh, K2
Sullivan, JP2
Kajiyama, S1
Kawamoto, M1
Shiraishi, S1
Gaus, S1
Matsunaga, A1
Suyama, H1
Yuge, O1
McGaraughty, S1
Chu, KL1
Cui, M1
Gauvin, D1
Hernandez, G1
Chandran, P1
Brown, B1
Bianchi, B1
McDonald, H1
Niforatos, W1
Neelands, TR1
Moreland, RB1
Decker, MW1
Chizh, BA1
O'Donnell, MB1
Napolitano, A1
Wang, J1
Brooke, AC1
Aylott, MC1
Bullman, JN1
Gray, EJ1
Lai, RY1
Williams, PM1
Appleby, JM1
Roberts, LA1
Connor, M1
Urban, L1
Campbell, EA1
Panesar, M1
Patel, S1
Chaudhry, N1
Kane, S1
Buchheit, KH1
Sandells, B1
James, IF2
Jaggar, SI1
Scott, HC1
Rice, AS1
Bingham, S1
Davey, PT1
Babbs, AJ1
Irving, EA1
Sammons, MJ1
Wyles, M1
Jeffrey, P1
Cutler, L1
Riba, I1
Johns, A1
Porter, RA1
Upton, N1
Hunter, AJ1
Parsons, AA1

Reviews

1 review available for urea and Allodynia

ArticleYear
TRPV1 antagonists as a potential treatment for hyperalgesia.
    Recent patents on CNS drug discovery, 2006, Volume: 1, Issue:1

    Topics: Analgesics; Animals; Humans; Hyperalgesia; Structure-Activity Relationship; TRPV Cation Channels; Ur

2006

Trials

1 trial available for urea and Allodynia

ArticleYear
The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans.
    Pain, 2007, Volume: 132, Issue:1-2

    Topics: Administration, Oral; Adolescent; Adult; Analgesics; Cohort Studies; Dose-Response Relationship, Dru

2007

Other Studies

23 other studies available for urea and Allodynia

ArticleYear
Involvement of 5-HT2A, 5-HT2B and 5-HT2C receptors in mediating the ventrolateral orbital cortex-induced antiallodynia in a rat model of neuropathic pain.
    Neuroreport, 2020, 01-27, Volume: 31, Issue:2

    Topics: Animals; Hyperalgesia; Indoles; Male; Neuralgia; Prefrontal Cortex; Rats, Sprague-Dawley; Receptor,

2020
Chemical stimulation of the lateral hypothalamus induces antiallodynic and anti-thermal hyperalgesic effects in animal model of neuropathic pain: Involvement of orexin receptors in the spinal cord.
    Brain research, 2020, 04-01, Volume: 1732

    Topics: Animals; Benzoxazoles; Carbachol; Disease Models, Animal; Dose-Response Relationship, Drug; Hot Temp

2020
Involvement of descending pain control system regulated by orexin receptor signaling in the induction of central post-stroke pain in mice.
    European journal of pharmacology, 2020, May-05, Volume: 874

    Topics: Adrenergic alpha-2 Receptor Antagonists; Animals; Benzoxazoles; Brain; Brain Ischemia; Hyperalgesia;

2020
Soluble epoxide hydrolase inhibitor trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl)urea prevents hyperalgesia through regulating NLRC4 inflammasome-related pro-inflammatory and anti-inflammatory signaling pathways in the lipopolysaccharide-induced pa
    Drug development research, 2021, Volume: 82, Issue:6

    Topics: Animals; Anti-Inflammatory Agents; Epoxide Hydrolases; Hyperalgesia; Inflammasomes; Intercellular Si

2021
Liposomal Delivery of Diacylglycerol Lipase-Beta Inhibitors to Macrophages Dramatically Enhances Selectivity and Efficacy in Vivo.
    Molecular pharmaceutics, 2018, 03-05, Volume: 15, Issue:3

    Topics: Animals; Anti-Inflammatory Agents; Behavior, Animal; Disease Models, Animal; Enzyme Inhibitors; Huma

2018
Mu-opioid Receptor (MOR) Biased Agonists Induce Biphasic Dose-dependent Hyperalgesia and Analgesia, and Hyperalgesic Priming in the Rat.
    Neuroscience, 2018, 12-01, Volume: 394

    Topics: Analgesics, Opioid; Animals; Dinoprostone; Dose-Response Relationship, Drug; Hyperalgesia; Injection

2018
Glycogen synthase kinase 3 beta regulates glial glutamate transporter protein expression in the spinal dorsal horn in rats with neuropathic pain.
    Experimental neurology, 2014, Volume: 252

    Topics: Amino Acid Transport System X-AG; Animals; Astrocytes; Disease Models, Animal; Drug Administration R

2014
Lateral Hypothalamic Stimulation Reduces Hyperalgesia Through Spinally Descending Orexin-A Neurons in Neuropathic Pain.
    Western journal of nursing research, 2016, Volume: 38, Issue:3

    Topics: Analgesics, Non-Narcotic; Animals; Benzoxazoles; Carbachol; Female; Hyperalgesia; Hypothalamic Area,

2016
Involvement of c-Myc-mediated transient receptor potential melastatin 8 expression in oxaliplatin-induced cold allodynia in mice.
    Pharmacological reports : PR, 2016, Volume: 68, Issue:3

    Topics: Animals; Benzyl Compounds; Ganglia, Spinal; Hyperalgesia; Male; Mice; Organoplatinum Compounds; Oxal

2016
Effect of transient receptor potential vanilloid 1 (TRPV1) receptor antagonist compounds SB705498, BCTC and AMG9810 in rat models of thermal hyperalgesia measured with an increasing-temperature water bath.
    European journal of pharmacology, 2010, Sep-01, Volume: 641, Issue:2-3

    Topics: Acrylamides; Animals; Bridged Bicyclo Compounds, Heterocyclic; Cold Temperature; Disease Models, Ani

2010
Endogenous N-acetylaspartylglutamate (NAAG) inhibits synaptic plasticity/transmission in the amygdala in a mouse inflammatory pain model.
    Molecular pain, 2010, Sep-22, Volume: 6

    Topics: Amygdala; Animals; Behavior, Animal; Dipeptides; Disease Models, Animal; Excitatory Postsynaptic Pot

2010
Transient receptor potential vanilloid 1 mediates pain in mice with severe sickle cell disease.
    Blood, 2011, Sep-22, Volume: 118, Issue:12

    Topics: Action Potentials; Anemia, Sickle Cell; Animals; Capsaicin; Disease Models, Animal; Female; Humans;

2011
Peripheral FAAH inhibition causes profound antinociception and protects against indomethacin-induced gastric lesions.
    Pharmacological research, 2012, Volume: 65, Issue:5

    Topics: Amidohydrolases; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experiment

2012
Glycogen synthase kinase 3-specific inhibitor AR-A014418 decreases neuropathic pain in mice: evidence for the mechanisms of action.
    Neuroscience, 2012, Dec-13, Volume: 226

    Topics: Analgesics; Animals; Arginine; Cytokines; Enzyme Inhibitors; Glycogen Synthase Kinase 3; Hyperalgesi

2012
Thrombin inhibits NMDA-mediated nociceptive activity in the mouse: possible mediation by endothelin.
    The Journal of physiology, 2003, Jun-15, Volume: 549, Issue:Pt 3

    Topics: Acetic Acid; Amino Acid Chloromethyl Ketones; Animals; Behavior, Animal; Capillary Permeability; End

2003
Novel transient receptor potential vanilloid 1 receptor antagonists for the treatment of pain: structure-activity relationships for ureas with quinoline, isoquinoline, quinazoline, phthalazine, quinoxaline, and cinnoline moieties.
    Journal of medicinal chemistry, 2005, Feb-10, Volume: 48, Issue:3

    Topics: Abdominal Pain; Administration, Oral; Analgesics; Animals; Biological Availability; Calcium; Cells,

2005
A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel transient receptor potential type V1 receptor antagonist, relieves pathophysiological pain associated with inflammation and tissue injury in rats.
    The Journal of pharmacology and experimental therapeutics, 2005, Volume: 314, Issue:1

    Topics: Acute Disease; Analgesics; Animals; Capsaicin; Carrageenan; Chronic Disease; Dose-Response Relations

2005
Spinal orexin-1 receptors mediate anti-hyperalgesic effects of intrathecally-administered orexins in diabetic neuropathic pain model rats.
    Brain research, 2005, May-17, Volume: 1044, Issue:1

    Topics: Animals; Behavior, Animal; Benzoxazoles; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Dos

2005
Systemic and site-specific effects of A-425619, a selective TRPV1 receptor antagonist, on wide dynamic range neurons in CFA-treated and uninjured rats.
    Journal of neurophysiology, 2006, Volume: 95, Issue:1

    Topics: Action Potentials; Animals; Evoked Potentials, Somatosensory; Freund's Adjuvant; Ganglia, Spinal; Hy

2006
TRPV1 receptors in the CNS play a key role in broad-spectrum analgesia of TRPV1 antagonists.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2006, Sep-13, Volume: 26, Issue:37

    Topics: Administration, Oral; Analgesics; Animals; Arthralgia; Calcium; Capsaicin; Cell Line; Cells, Culture

2006
In vivo pharmacology of SDZ 249-665, a novel, non-pungent capsaicin analogue.
    Pain, 2000, Dec-15, Volume: 89, Issue:1

    Topics: Analgesics; Animals; Behavior, Animal; Blinking; Blood Pressure; Bronchoconstriction; Capsaicin; Car

2000
The capsaicin analogue SDZ249-665 attenuates the hyper-reflexia and referred hyperalgesia associated with inflammation of the rat urinary bladder.
    Pain, 2001, Volume: 89, Issue:2-3

    Topics: Algorithms; Analgesics; Animals; Capsaicin; Cystitis; Dose-Response Relationship, Drug; Hyperalgesia

2001
Orexin-A, an hypothalamic peptide with analgesic properties.
    Pain, 2001, Volume: 92, Issue:1-2

    Topics: Abdomen; Analgesics; Anesthesia, Intravenous; Animals; Behavior, Animal; Benzoxazoles; Carrageenan;

2001